BioRestorative Therapies, Inc. 8-K

What Happened
BioRestorative Therapies, Inc. filed an 8-K on June 12, 2026 disclosing that on June 10, 2026 the company and Francisco Silva, its Vice President, Research and Development, entered into an employment agreement. The agreement provides for a term ending June 10, 2029 and sets Mr. Silva’s annual salary at $575,000 (the same amount currently in effect).

Key Details

• Agreement date: June 10, 2026; 8-K filed: June 12, 2026.
• Employment term expires: June 10, 2029.
• Annual base salary: $575,000 (no change from current salary).
• Full Employment Agreement is filed as Exhibit 99.1 to the Form 8-K.

Why It Matters
This filing documents the company’s formal agreement to retain its VP of R&D for a multi-year term, signaling continuity in research and development leadership. For investors, the item is a governance/compensation disclosure rather than financial results; the disclosed base salary remains unchanged. Investors seeking details on other compensation elements (bonuses, equity, severance) should review the full Employment Agreement in Exhibit 99.1.